mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance
about
The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic VariantsmCSM-NA: predicting the effects of mutations on protein-nucleic acids interactions.Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance.SDM: a server for predicting effects of mutations on protein stability.Combating mutations in genetic disease and drug resistance: understanding molecular mechanisms to guide drug design.Mapping genetic variations to three-dimensional protein structures to enhance variant interpretation: a proposed framework.Familial STAG2 germline mutation defines a new human cohesinopathy.Recent advances in automated protein design and its future challenges.Prediction and interpretation of deleterious coding variants in terms of protein structural stability.Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.Kinact: a computational approach for predicting activating missense mutations in protein kinases.Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae.DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability.Structural and Biochemical Insights into the Function and Evolution of SulfoquinovosidasesUnderstanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosisRole of Disputed Mutations in the Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis
P2860
Q27728459-DDD85182-C614-43DB-B4AE-4A6F80C5E60BQ28396379-0C09D250-9B1E-4CE9-B001-BA3D38F62441Q30400796-874893D9-DCB4-4BAE-9C61-FB170B0C1132Q38730555-4876A3F3-108E-459E-8F50-8ED01C631A78Q38774417-2CB0C837-EA30-4BEB-AEF2-E26435A658B7Q39296374-EB119853-A65C-407A-BC13-23204C847F2FQ47147684-48335FD0-93D5-4B5F-87CD-6756BC2AE97DQ47165215-1E293CC9-1854-4950-8FB7-3A0152551BD4Q52309659-88695D33-C968-42CF-92F4-6F714EC527B5Q52355362-23AD14F6-A164-406B-91A0-39CC1E8D7EB9Q53701648-73B82FCB-2078-4E2B-A594-1AF0B30E45FAQ53701660-C986122C-1B80-4ABA-9EF1-3FDA312FA197Q54978537-5E0DE9B0-1C85-4B7C-8755-D01C1F8DE370Q55108179-6AE24F45-B7D0-4FB9-A024-B273FBE15DE4Q55479193-C5200302-41EE-4F37-B5C9-2F8A9C3143F1Q57068907-93D6F05F-94EB-4AF8-AA4B-6E06E977AA78Q57954019-0FB25B22-6CAF-433E-A79A-A7DA1430D903Q58865294-0B22086A-1F1C-4A0B-A941-ADDC54F8C9FF
P2860
mCSM-lig: quantifying the effects of mutations on protein-small molecule affinity in genetic disease and emergence of drug resistance
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@ast
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@en
type
label
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@ast
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@en
prefLabel
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@ast
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@en
P2860
P50
P3181
P356
P1433
P1476
mCSM-lig: quantifying the effe ...... d emergence of drug resistance
@en
P2093
Douglas E V Pires
P2860
P2888
P3181
P356
10.1038/SREP29575
P407
P577
2016-07-07T00:00:00Z
P6179
1004269651